Customize
Quick Links

Accreditation/
Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians' Education Resource®, LLC, designates this live activity for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

About
Accreditation
Privacy Policy
Terms & Conditions
Executive Board
Journal
Faculty Portal
Contact
Facebook
Twitter
LinkedIn
Google +
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 1-609-378-3701

Copyright © 2019
Physicians’ Education Resource ®, LLC.
All rights reserved.

Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting

Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting


May 3, 2019
8:00 AM - 10:00 AM

McCormick Place West
W375B (Level 3)
2301 S. Martin Luther King Drive
Chicago, Illinois 60616

Overview:

Renal cell carcinoma (RCC) has been one of the most difficult to treat of the solid tumors, and more recently, one of the most rapidly evolving fields in oncology. New data suggest impending changes to your practice in both early-stage and metastatic RCC, including novel indications, combination approaches, and optimized adjuvant strategies. The use of adjuvant therapy for RCC remains an area of controversy for which high-quality, well-coordinated, multidisciplinary care is of utmost importance to achieving optimal outcomes.

Please join us for Transforming Treatment Paradigms in Renal Cell Carcinoma: Understanding the Role of Risk Stratification and Emerging Data in the Adjuvant Setting, a satellite symposium that will be held adjunct to the annual urology meeting in Chicago. In this program, a multidisciplinary panel of renowned experts in RCC will guide you through an in-depth, up-to-date review of risk assessment in the early-stage RCC setting, surgical standards-of-care and challenges, patient selection for adjuvant systemic therapy, evidence from clinical studies of adjuvant therapy for RCC, and overall multidisciplinary care planning. To help you apply this information and to provide you with opportunities to interact with the faculty and one another, this activity includes case-based discussions and a Medical Crossfire® debate on key areas of controversy and clinical uncertainty regarding the use of adjuvant therapy for RCC.

By participating in this exciting program, you will learn:

  • Perspectives on early-stage RCC management from specialists in surgery, urology, and medical oncology
  • Best practices for risk assessment and patient selection for adjuvant RCC therapy
  • How to integrate data from trials of adjuvant systemic therapy for RCC into overall multidisciplinary care planning
  • How to balance the potential benefits and risks of each therapeutic option in the adjuvant setting

Acknowledgment of Commercial Support

This activity is supported by an educational grant from Pfizer Inc.

Program Chair

Robert A. Figlin, MD, FACP
Steven Spielberg Family Chair in Hematology Oncology
Professor of Medicine and Biomedical Sciences
Director, Division of Hematology Oncology
Deputy Director, Integrated Oncology Service Line
Deputy Director, Samuel Oschin Comprehensive Cancer Institute
Cedars-Sinai Medical Center
Los Angeles, CA







Become a Member

Forgot Password?
Calendar of Events
SUNMONTUESWEDTHURSFRISAT
     12
3456789
10111213141516
17181920212223
2425262728
Filter By